Adult participants with metastatic (advanced) solid tumors
Conditions
Brief summary
Antitumour activity will be assessed in terms of objective response rate (ORR) RECIST v1.1, independently for each cohort :
Detailed description
24-weeks clinical benefit rate (CBR), Best overall response throughout the treatment period (BoR), Duration of response from documentation of tumour response to disease progression (DoR), 1-year and 2-year progression-free survival (PFS), Growth modulation index (GMI), 1-year and 2-year overall survival (OS), Safety profile of volrustomig, Correlate tumor microenvironment features (including but not limited to density of immune cells, expression of exhaustion markers), plasma metabolomics, plasma proteomics with patient outcome (objective response rate, PFS and OS).
Interventions
DRUGvolrustomig
Sponsors
Institut Bergonie
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Antitumour activity will be assessed in terms of objective response rate (ORR) RECIST v1.1, independently for each cohort : | — |
Secondary
| Measure | Time frame |
|---|---|
| 24-weeks clinical benefit rate (CBR), Best overall response throughout the treatment period (BoR), Duration of response from documentation of tumour response to disease progression (DoR), 1-year and 2-year progression-free survival (PFS), Growth modulation index (GMI), 1-year and 2-year overall survival (OS), Safety profile of volrustomig, Correlate tumor microenvironment features (including but not limited to density of immune cells, expression of exhaustion markers), plasma metabolomics, plasma proteomics with patient outcome (objective response rate, PFS and OS). | — |
Countries
France
Outcome results
None listed